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Combination antiretroviral therapy (CART) dramatically decreases mother-to-child HIV-1 transmission (MTCT), but maternal
adverse events are not infrequent. A review of 117 locally followed pregnancies revealed 7 grade ≥3 AEs possibly related
to antiretrovirals, including 2 hematologic, 3 hepatic, and 2 obstetric cholestasis cases. A fetal demise was attributed to
obstetric cholestasis, but no maternal deaths occurred. The drugs possibly associated with these AE were zidovudine, nelﬁnavir,
lopinavir/ritonavir, and indinavir. AE or intolerability required discontinuation/substitution of nevirapine in 16% of the users,
zidovudine in 10%, nelﬁnavir in 9%, lopinavir/ritonavir in 1%, but epivir and stavudine in none. In conclusion, nevirapine,
zidovudine, and nelﬁnavir had the highest frequency of AE and/or the lowest tolerability during pregnancy. Although nevirapine
and nelﬁnavir are infrequently used in pregnancy at present, zidovudine is included in most MTCT preventative regimens. Our
dataemphasizetheneedtorevisethetreatmentrecommendationsforpregnantwomentoincludesaferandbetter-tolerateddrugs.
1.Introduction
Combination antiretroviral therapy (CART) has decreased
HIV mother-to-child-transmission (MTCT) to <2% in the
USA and other countries where ART is readily available
[1–5]. To reliably achieve suppression of maternal HIV
replication, which is essential for prevention of MTCT,
information on the safety and tolerability of drug regimens
for HIV-infected pregnant women is critically important.
Antiretroviral regimens recommended by the WHO
for PMTCT (http://www.who.int/hiv/pub/mtct/antiretrovi-
ral2010/en/index.html) include zidovudine (AZT) and
lamivudine (3TC) with a single dose of nevirapine (NVP)
at delivery or AZT/3TC with lopinavir/ritonavir (LPV/RTV),
with efavirenz (EFV; only in the 2nd trimester or later) or
with abacavir (ABC) for the entire duration of treatment
in pregnancy. Overall, the most commonly used nucleoside
reverse transcriptase inhibitors (NRTIs) during pregnancy
are AZT and 3TC [6]. Some NRTIs are avoided during
pregnancy due to their toxicity, such as didanosine (DDI)
with stavudine (D4T) [7]. NVP was associated in some
studies with a high level of hepatotoxicity in women with
CD4 > 200cells/µL[ 8, 9]. Although this observation was
not conﬁrmed in other studies [10, 11], NVP is currently
recommended only as a single dose at delivery or in women
with CD4< 250cells/µL. Tenofovir (TNV) has not been
extensively studied in pregnancy. Its use is limited because
of its eﬀect on bone mineralization [12, 13].
Although CART for the mother clearly reduces the risk
of HIV MTCT, it is not universally used for this purpose
becauseofthehighcostofdrugs,concernwiththesafetyand
tolerability of diﬀerent classes of antiretrovirals [14–19]a n d
with the potential emergence of drug resistance in mothers
who stop CART after delivery [20–23]. In a previous study,
we showed that the use of CART by 117 women in our clinic
during pregnancy was not associated with drug resistance
[24]. This was subsequently conﬁrmed by similar ﬁndings in
other studies [25].2 Infectious Diseases in Obstetrics and Gynecology
The objective of this study was to evaluate the safety
and tolerability of diﬀerent components of CART during
pregnancy.
2.MaterialandMethods
2.1.StudyDesign. Thiswasaretrospectivechartreviewstudy
of CART utilization and adverse events (AEs) in pregnan-
cies managed by the Children’s Human Immunodeﬁciency
Program (CHIP) in Denver, Colo between August 1997 and
December 2005, as previously described [26]. Basic CART
consisted of ≥3ARV representing ≥2classes. Hematology,
chemistry, and liver function tests were done at 4- to 8-week
intervals. For this report, we collected and analyzed AE for
pregnancies of at least 16 weeks duration and with at least
2 visits to CHIP and drug substitutions due to grade ≥3AE
or intolerance of ART, deﬁned as inability to tolerate nonlife
threatening clinical AEs, such as headache, nausea, diarrhea,
or other subjective disorders. AEs were classiﬁed as per the
Division of AIDS Table for Grading the Severity of Adult and
Pediatric Adverse Events, Version 1.0, dated December, 2004
(http://rcc.tech-res.com/safetyandpharmacovigilance/).
2.2. Statistical Analyses. We utilized a two-sided test of
hypothesis with a signiﬁcance level of.05, and it was per-
formed in SAS v9.2. Characteristics are presented as medians
with interquartile ranges or number (N)a n dp e r c e n ti na
category, as appropriate. McNemar’s test was used to assess
whether AZT and D4T were more likely to be added versus
discontinued during pregnancy.
3. Results
3.1. Demographics and HIV-Disease Characteristics. Of 124
pregnancies that met inclusion criteria, complete medical
records were available on 117pregnancies including 12
women with 2 pregnancies (Table 1). Median gestational age
at delivery was 38 weeks (interquartile range (IQR)=37–
40weeks). Of 120 infants (3twin gestations), 2 were still-
born, 1 died of sepsis at 1 day of life, and 117 survived and
were free of HIV.
3.2. Antiretrovirals and AEs during Pregnancy. The median
duration of continuous therapy during pregnancy was 22
weeks (IQR=15–35weeks). Among 115 evaluable women
at delivery, 106 (94%) were on CART (≥3d r u g sf r o m≥2
classes); 7women (4%) were on 2 or 3 NRTI due to lack of
tolerance of CART; 1 woman was on AZT monotherapy, and
1 woman refused ART.
Hematologic, metabolic, hepatic, and pancreatic AEs
identiﬁed by routine testing were conﬁrmed by repeat testing
(Table 2). Grade ≥3 anemia was documented in 2 patients
(2%), one of whom also had thrombocytopenia. Both
womenwerereceivingAZTwhenhematologicabnormalities
developed. Laboratory values improved after AZT discontin-
uation suggesting that AZT caused the SAE. Five additional
subjects, including 4 on AZT, had grade 1 or 2 hematologic
AEs.
Table 1: Demographics and baseline characteristics of HIV infec-
tion.
Characteristic N or Median (% or IQR)
Pregnant patients 105
One pregnancy with CHIP 93 (89)
Two pregnancies with CHIP 12 (11)
Maternal age at delivery 30 (26, 34)
Race
White 72 (68.6)
Black 31 (29.5)
Other 2 (1.9)
Ethnicity
Hispanic 41 (39)
Not hispanic 64 (61)
HIV risk factors†
IV drug use 12 (11)
Heterosexual sex 98 (92)
Transfusion 5 (5)
Timing of HIV diagnosis
Prior to ﬁrst pregnancy at CHIP 70 (67)
During ﬁrst pregnancy at CHIP 35 (33)
Antiretroviral therapy at the onset
of pregnancy 29 (25)
Plasma HIV RNA at ﬁrst visit 109 pregnancies
Median (quartiles) 2657 (225, 16700)
>400copies/mL 78 (72)
CD4+ count at ﬁrst visit 108 pregnancies
Median (quartiles) 450 cells/µL (269, 628)
<200cells/µL 13 (12%)
†Some subjects had multiple risk factors.
There were 4 grade≥3hepatobiliary SAE in 3 of 99
evaluable women (3%), including one with 2 pregnancies.
Two women had underlying liver disease caused by hepatitis
C virus or hepatic steatosis. The drugs deemed probably
responsible for the SAE were ritonavir- (RTV-) boosted
saquinavir (SAQ), indinavir (IDV), nelﬁnavir (NFV), and
AZT. Fifteen pregnancies (15%) were complicated by grade
1 or 2 liver function abnormalities, none of which required
ARV changes.
Of 69 women with amylase measurements, 3 (4%) had
grade 1 or 2 transient elevations, which normalized without
any intervention and, therefore, could not be ascribed to
ARV.
Two women were diagnosed with obstetric cholestasis
(OC) deﬁned by pruritic rash and elevated bile acids. One
of them with chronic hepatitis C infection had a nonviable
fetus at the time of OC diagnosis. The other individual
without underlying liver disease delivered a healthy infant
by Cesarean section. Both individuals were on PI-containingInfectious Diseases in Obstetrics and Gynecology 3
Table 2: Laboratory adverse events.
Adverse event N tested# N (%) with adverse event
Grades 4∗ Grades 3∗ Grades 2∗ Grades 1∗
Anemia 110 2 (2%) 0 1 (1%) 4 (4%)
Thrombocytopenia 110 0 1 (1%) 0 2 (2%)
Neutropenia 110 0 0 3 (3%) 1 (1%)
Elevated ALT 98 1 (1%) 1 (1%) 4 (4%) 6 (6%)
Elevated AST 99 0 2 (2%) 4 (4%) 8 (8%)
Elevated bilirubin 98 2 (2%) 0 1 (1%) 2 (2%)
Elevated alkaline phosphatase 96 0 0 2 (2%) 17 (18%)
Elevated amylase 69 0 0 2 (3%) 1 (1%)
∗AE grades are the maximum observed grade for each pregnancy. Grading was performed according to the Division of AIDS Table for Grading the Severity
of Adult and Pediatric Adverse Events, Version 1.0, dated December 2004 (http://rcc.tech-res.com/safetyandpharmacovigilance/).
Table 3: Drug substitutions or discontinuations during pregnancy.
Class Drug N events/N
pregnancies
Percent (95%
conﬁdence interval)
NRTI 11/114# 10 (5–17)
AZT 10/99 10 (5–18)
3TC 0/109 0 (0–3)
d4T 0/23 0 (0–15)
ABC 1/8 13 (0–53)
ddI 0/6 0 (0–46)
TDF 0/2 0 (0–84)
FTC 0/1 0 (0–98)
NNRTI 3/20#∗ 15 (3–38)
NVP 3/19 16 (1–33)
DLV 0/1 0 (0–98)
EFV 2/2 n.a.
PI 8/97# 8 (4–16)
NFV 6/64 9 (4–19)
LPV/RTV 2/28 1 (1–24)
IDV 0/5 0 (0–60)
IDV/RTV 0/1 0 (0–98)
SQV 0/2 0 (0–84)
SQV/RTV 2/9 22 (3–60)
∗Excludes EFV substitutions.
#In the drug class summary, a pregnancy in which ≥2d r u g sf r o mt h es a m e
c l a s sw e r es u b s t i t u t e dw a sc o u n t e do n l yo n c e .
regimens at the time OC was diagnosed: one on NFV and
one on lopinavir (LPV) with RTV boost. The patient with
underlying hepatitis C had a subsequent pregnancy, during
which she received a triple NRTI regimen (AZT/3TC/ABC).
She did not develop OC and delivered a healthy, uninfected
infant.
Two women developed rashes while on NVP, which
improved after NVP discontinuation. There were other
clinical AE, including nausea, vomiting, diarrhea, perioral
paresthesias, headache, and insomnia that prompted drug
discontinuations.
3.3. Changes in ART Caused by ARV Intolerance during
Pregnancy. Grade ≥3 AE or poor tolerability prompted 17
changes in therapy in 16 out of 117 pregnancies (14%;
Table 3).
There were 11 NRTI substitutions in 114 women
receiving NRTI (10%). Ten involved AZT and were due to
hematologic SAE, progressive anemia, which in the opinion
of the health care provider would reach grade ≥3 before the
endofpregnancy,headache,insomnia,orgastricdiscomfort.
Overall, AZT was more likely to be discontinued than added
(P = .004, McNemar’s test). AZT was most commonly
s u b s t i t u t e db yD 4 T ,w h i c hw a sm o r el i k e l yt ob ea d d e d
than discontinued (P = .02, McNemar’s test). The average
durations of AZT and D4T therapy during pregnancy were
similar at 140 and 111 days, respectively (SD=83 and 73,
resp.).
NNRTI substitutions occurred in 3 of 21 women (14%)
receiving NNRTI other than efavirenz (EFV). All occurred
among 19 women on NVP. EFV was substituted in 2 women
who inadvertently became pregnant while on EFV. Their
infants did not have any gross abnormalities at birth or
during follow-up.
P Is u b s t i t u t i o n so c c u r r e di n8o f9 7p r e g n a n c i e s( 8 % )
with PI-containing CART. LPV/RTV and NFV were the PI
most commonly administered. LPV/RTV was used in 28
pregnancies and was substituted or discontinued due to
toxicity or lack of tolerability in 2 women (1%). NFV was
s u b s t i t u t e di n6( 9 % )o f6 4w o m e n .O t h e rP I s ,s u c ha s
saquinavir and indinavir, were less commonly used.
4. Discussion
In this study, 8% of pregnancies were complicated by grade
≥3 AE probably or possibly due to ARV which is similar to
previous reports [27–29] .S A Ep r o b a b l yo rp o s s i b l yr e l a t e d
to the use of ARV included 3 hematologic, 4 hepatic, and4 Infectious Diseases in Obstetrics and Gynecology
2OC. One woman had multiple SAE during 2 pregnancies.
The incidence of ARV-associated SAE and the rate of drug
substitutions did not signiﬁcantly diﬀer across classes of
drugs, suggesting that they were equally safe and well
tolerated during pregnancy.
Among NRTI, AZT was the most poorly tolerated drug.
In the ﬁrst AZT trial for PMTCT [30], the incidence of AE
in mothers receiving AZT monotherapy was similar to that
in placebo recipients. However, HIV replication was poorly
controlled in that study and may have contributed to the
overall incidence of AE. Other studies using combination
therapy during pregnancy showed frequent hematologic
toxicitiesinmothersandchildrenwhoreceivedAZT[27,31–
33]. In our study, although mothers who developed hemato-
logic SAE ascribed to AZT were receiving combination ART
at the time of the event, laboratory values improved after
AZT substitution, suggesting that AZT was responsible for
the AE. Despite its marginal safety and tolerability during
pregnancy, AZT is the main drug recommended by USPHS
and WHO for PMTCT. This is partly due to the reluctance
to substitute a drug with proven eﬃcacy. However, CART
has higher or equal eﬃcacy for PMTCT than AZT alone,
making it possible to substitute AZT with other drugs to
avoid undesirable side eﬀects.
Drugs that could potentially substitute AZT in combi-
nation ART for PMTCT are TNV, ABC, and D4T, all of
which synergize with 3TC. The Antiretroviral Pregnancy
Drug Registry includes data on ≥628 pregnancies for each
of these drugs with a rate of congenital birth defects similar
to that of the general population [6]. Although these drugs
appear nonteratogenic, they face other limitations. TNV
interferes with bone formation in experimental animals
[13]. In small numbers of reports in humans, results were
variable [34, 35], and, therefore, providers tend to avoid
TNV in pregnancy. The use of ABC is limited by its
potential allergic reactions. This risk can be mitigated by
HLA B5701 detection, which deﬁnes the likelihood of ABC
hypersensitivity [36]. In pregnancy, drug changes have to
be quickly implemented, which may not be compatible
with the delay required for HLA typing. Finally, D4T has
been associated with peripheral neuropathy, lactic acidosis
and other metabolic abnormalities including lipodystrophy
[37, 38]. Nevertheless, this drug continues to be widely
used in resource-limited countries. In our experience, D4T
administered for a limited period of time during pregnancy
was well tolerated. The average duration of treatment with
D4T and AZT were similar in this study, but patients did not
have to discontinue D4T during pregnancy. These ﬁndings
are consistent with other studies that showed a lower rate of
substitutionofD4TcomparedtoAZTinnonpregnantadults
[39,40].Furthermore,D4Tcrossestheplacentaandachieves
suﬃcient levels in the fetus for pre-exposure prophylaxis.
Although based on a limited number of observations (N =
23), our data suggest that D4T may be a viable alternative to
AZT during pregnancy.
NNRTI are uncommonly used during pregnancy other
than single-dose NVP at delivery. EFV is contraindicated in
the ﬁrst trimester due its potential teratogenicity [41]. EFV
has recently been included in the WHO recommendations
for combination ART after ≥14 weeks of gestations, but
its use is still limited. Delavirdine and etravirine have been
insuﬃciently studied during pregnancy. NVP, which was
widely used for PMTCt in the late 1990s, is currently
contraindicated in pregnant women with ≥250CD4cells/µL
due to potential hepatic and cutaneous toxicity. In this
study, NVP was used in 19 women with a median ﬁrst visit
CD4 of 419 (IQR=205–588). Three (16%) required NVP
substitution due to mild or moderate AE.
NFV, the PI most commonly used in this study was
poorly tolerated in 6 of 64 women (9%). The second most
commonly used PI was LPV/RTV, which was well tolerated
by 26 of 28 women. Three women developed 4 episodes of
grade ≥3 hepatic AE, 3 of which were associated with PI
(NFV, SAQ/RTV and indinavir). In addition, two cases of
OC were diagnosed in women receiving PI. The relationship
betweenOCandARVisnotclear.TheARVRegistryincludes
veryfewepisodesofOC,buttheregistry,whichwasdesigned
for birth defects, does not systematically collect other AE,
which may underestimate their incidence, including OC.
OC resulting from a pregnancy-speciﬁc accumulation of
bile acids is associated with fetal demise [42]. The risk
of OC is increased by chronic hepatitis C infection [43],
which was present in one of our study women, and by
other chronic liver conditions. Otherwise, OC is quite
uncommon in Europeans, with an incidence of 0.1 to 2%,
but quite common in Chile (9 to 16%), possibly related
to the genetic background of the population [44, 45]. PI
and other ARV have hepatotoxic potential [11, 46] that may
contribute to OC. This hypothesis deserves to be further
studied.
In conclusion, the safety and tolerability of CART in
pregnancy did not diﬀer by class of ARV, but there were
diﬀerences among individual drugs. Drugs with the poorest
safety and tolerability were AZT, NVP, and NFV. Our
ﬁndings support the need to devise new CART regimens for
PMTCT that will avoid the use of poorly tolerated drugs.
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